utd_medknow
Indian Journal of Cancer
Home  ICS  Feedback Subscribe Top cited articles Login 
Users Online :453
Small font sizeDefault font sizeIncrease font size
Navigate Here
     My Preferences 
     Manuscript submission

 


This article has been cited by
1Outcomes According to ALK Status Determined by Central Immunohistochemistry or Fluorescence In Situ Hybridization in Patients With ALK-Positive NSCLC Enrolled in the Phase 3 ALEX Study
Tony Mok,Solange Peters,D. Ross Camidge,Johannes No,Shirish Gadgeel,Sai-Hong Ignatius Ou,Dong-Wan Kim,Krzysztof Konopa,Emanuela Pozzi,Ting Liu,Isabell R. Loftin,Crystal Williams,Alice T. Shaw
Journal of Thoracic Oncology.2021;16(2)259
[DOI]
2Combination of crizotinib and chemotherapy in patients with relapsed or refractory anaplastic lymphoma kinase (ALK)-positive anaplastic large cell lymphoma (ALCL)
Mei-ting Chen,Xiao-hong Fu,He Huang,Zhao Wang,Xiao-jie Fang,Yu-Yi Yao,Quan-Guang Ren,Ze-geng Chen,Tong-yu Lin
Leukemia & Lymphoma.2021;62(3)571
[DOI]
3ALK Inhibitors in Nonsmall Cell Lung Cancer
Nitish Garg,Rushabh Kothari
Indian Journal of Medical and Paediatric Oncology.2021;42(01)067
[DOI]
4Lack of expression of ALK and CD30 in breast carcinoma by immunohistochemistry irrespective of tumor characteristics
Samer Nassif,Ziad M. El-Zaatari,Michel Attieh,Maya Hijazi,Najla Fakhreddin,Tarek Aridi,Fouad Boulos
Medicine.2019;98(32)e16702
[DOI]
  Site Map | What's new | Copyright and Disclaimer
  Online since 1st April '07
  2007 - Indian Journal of Cancer | Published by Wolters Kluwer - Medknow